Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Touts Advances with Lipid, Conjugate Delivery Technologies


Alnylam Pharmaceuticals said this week that it and collaborators have developed a novel class of lipid nanoparticles capable of greater target inhibition than the company's existing lipid delivery agents.

According to the company, the so-called reLNPs demonstrate “potent target gene silencing in vivo, with an ED50 at doses of less than 0.05 mg/kg while demonstrating tolerability at doses exceeding 10 mg/kg.”

This represents a roughly 10-fold improvement over the company's second-generation MC3 lipids, and an approximately 100-fold increase in efficacy over first-generation technologies.

The MC3 lipid is currently at issue in a lawsuit between Alnylam and partner Tekmira Pharmaceuticals (GSN 8/18/2011).

Alnylam also said that it has made improvements to its early-stage GalNAc conjugation technology for siRNA delivery

“Improvements in chemistry lead to markedly increased potency for in vivo target gene silencing with GalNAc-conjugated siRNAs administered by subcutaneous injection at low, clinically relevant doses,” Alnylam said.

Meanwhile, administration of GalNAc-conjugated siRNAs against transthyretin, the target of the firm's phase I transthyretin-mediated amyloidosis therapy ALN-TTR01, resulted in robust gene silencing in preclinical animal models with an ED50 of approximately 5 mg/kg after a single subcutaneous injection.

Earlier this year, Alnylam CEO John Maraganore called conjugate-based delivery approaches “the future for delivery of small interfering RNAs” (GSN 6/2/2011).

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.